Bloodstream Infection Testing Market size was over USD 7 Billion in 2023 and is projected to reach USD 28 Billion by the end of 2036, growing at around 9% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of bloodstream infection testing is evaluated at USD 11 Billion.
The growing frequency of infectious diseases is the key factor driving the market growth of bloodstream infection testing. The increasing population and limited constancy to hygiene practices increase the possibility of infectious diseases. According to the World Health Organization, in 2020, there were around 48.9 million cases and 11 million deaths caused due to sepsis worldwide, representing 20% of all global deaths.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
9% |
|
Base Year Market Size (2023) |
USD 7 Billion |
|
Forecast Year Market Size (2036) |
USD 28 Billion |
|
Regional Scope |
|
Product (Instruments, Reagents & Consumables)
Reagents & consumables segment is expected to dominate bloodstream infection testing market share of over 69% by 2036. The segment growth can be attributed to the effortless availability and high purchase of screening products for blood donors and recipients.
Moreover, the broad range of blood grouping, typing, and donor screening reagents, kits, and assays which are offered by global and local manufacturers drive the growth of consumables segment. According to the United Nations Children’s Fund (UNICEF), the number of AD syringes UNICEF procured grew from 11 million in 1997 to around 600-800 million per year. It is also the world’s largest buyer of AD syringes, procuring 40% of the global market.
Application (Bacterial, Fungal, Mycobacterial)
In bloodstream infection testing market, bacterial segment is set to account for revenue share of around 65% by 2036. The segment growth can be attributed to the increasing cases of bacterial infections such as pneumonia or meningitis. Bacteria can enter the bloodstream of the human body as a severe side effect of other infections during surgery or due to catheters.
Moreover, bacterial infections in the blood can have several serious health effects. According to WHO, around half (20 million) of all predicted sepsis cases recorded across the world occurred in children under 5 years of age, and for every 1000 hospitalized patients, around 15 patients will develop sepsis as a complication of receiving health care. Furthermore, increasing cases of sepsis are foreseen to be the major driving factor for the market.
End-User (Hospitals, Independent Diagnostics Centers, Others)
By 2036, hospital segment is estimated to capture bloodstream infection testing market share of over 55%. The reason behind segment growth is the increasing number of hospitals as these are the primary place for diagnosis of bloodstream infection. The patient with symptoms of bloodstream infection first gets in touch with the hospital, as these places are equipped with advanced technologies including diagnostic laboratories, equipment, and experienced healthcare professionals.
They frequently perform a high volume of bloodstream infection tests on both inpatients and outpatients, making them a key player in the market. As per the latest report, more than 317,705 hospital admissions took place due to sepsis during the period from 2008 to 2021. Around 222,832 of the patients were admitted to hospital for the first time due to sepsis. Moreover, the improving healthcare facilities in developing countries along with the growing number of independent laboratories with hospital beds and supporting equipment is the main factor driving the bloodstream infection testing market.
Our in-depth analysis of the global market includes the following segments:
|
Product |
|
|
Sample |
|
|
Technology |
|
|
Application |
|
|
End-User |
|
North American Market Statistics
North America region in bloodstream infection testing market is expected to dominate revenue share of over 34% by 2036. This growth can be impelled by the rapid growth in the geriatric population with a large number of healthcare facilities available.
According to the United States Census Bureau, the geriatric population reached 55.8 million, or 16.8% of the population of the United States in 2020. The blood disorders reported in the population are non-cancerous blood disease which makes it easier to treat them.
The presence of major key players in the US who started investing more in the research and development of bloodstream infection testing devices, is evaluated to create opportunities in the market share through 2036. As per a recent report, medical device startups raised in the US to USD 8.8 billion in venture capital in 2023, falling nearly 62% since 2020.
Healthcare-associated infections (HAIs) create a significant risk to the safety and quality of care of the patient. For instance, The Canadian Nosocomial Infection Surveillance Program (CNISP) conducts national surveillance of HAIs at sentinel acute-care hospitals across Canada and recorded that around 4,300 device-associated blood infections were reported in 2020.
APAC Market Analysis
The Asia Pacific region will also encounter huge growth for the bloodstream infection testing market between 2024 and 2036, and will hold the second position owing to the high rate of bloodstream infections in the region. Rapid economic growth in various parts of Asia has increased investments in medical technologies and healthcare spending. This has resulted in easier adoption of the latest technologies made in bloodstream infection testing tools. According to a recent study, a multicenter investigation of 2,773 cases of bloodstream infections was reported based on the China Antimicrobial Surveillance Network (CHINET).
Infectious illness control due to the presence of blood donors has become a major concern due to the high population density and mobility of China. As per a recent report, in 2021, the blood donation rate in China was 12 donations per 1000 individuals which is not enough to satisfy the nation's essential blood demand. The demand for blood continues to grow with the rapid growth of healthcare service requirements among the geriatric population of the region.
According to Annals of Laboratory Medicine, ESBL-EC (extended-spectrum β-lactamase-producing Escherichia coli) causes the majority of the bloodstream infections in Korea and around, 27% of community-onset E. coli bloodstream infections were caused by ESBL producers.
The major players in the bloodstream infection testing market are offering a detailed portfolio of blood test-related products. These companies introduced advanced technologies that enable detailed visualization of blood test procedures.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?